The cosmetic surgery, facial aesthetics and medical lasers market is expected to double in size by 2017, exceeding $3 billion, according to a new reoprt from medical device and pharmaceutical market research company iData Research.
The aesthetic laser and light therapy markets for skin resurfacing, hair removal and laser lipolysis will be the fastest growing segments, according to the report, and the market for botulinum toxin-A drugs, such as Botox, is estimated to grow to $543 million by 2017.
“Allergan has had a monopoly on botulinum toxin A drugs since 2002, but now faces competition from Dysport by Medicis as well as other new competitors expected to enter the market,” said Dr. Kamran Zamanian, CEO of iData. One of those future competitors may be a botulinum toxin called PurTox by Mentor. PurTox is now in Phase III clinical trials in the U.S., according to Mentor’s website.
The use of botulinum toxins is also expected to increase due to an increasing number of therapeutic treatments, such as upper limb spasms, neck malpositioning and certain types of eye muscle disorders. The FDA is also currently evaluating Botox as a treatment for severe migraines.
“A growing number of doctors are looking at the therapeutic potential of Botulinum-A. There are more cosmetic procedures performed using Botulinum-A than therapeutic, however therapeutic procedures use higher doses of the drug, therefore these two markets are similar in value,” said Dr. Zamanian.
The report, titled “Markets for Cosmetic Surgery, Facial Aesthetics and Medical Laser Devices 2011,” states that the U.S. market for injectables is valued at almost $860 million. The three-report series includes data, analyses, and competitor profiles for botulinum toxins, dermal fillers, breast augmentation implants, liposuction aspirators, laser/light devices, and microdermabrasion.
